Trulieve Announces Closing of Underwritten Offering of Subordinate Voting Shares



TALLAHASSEE, Fla., Sept. 21, 2020 (GLOBE NEWSWIRE) — Trulieve Cannabis Corp. (“Trulieve” or the “Company”) (CSE: TRUL) (OTCQX: TCNNF), a leading and top-performing cannabis company in the United States, today announced that it has closed its previously announced underwritten offering of 4,715,000 subordinate voting shares of the Company (the “Offered Securities”) at a price of C$24.50 per Offered Security, for aggregate gross proceeds to Trulieve of C$115,517,500, which includes the full exercise of the over-allotment option (the ”Offering”) by the underwriters.

Canaccord Genutiy Corp. acted as lead underwriter for the Offering, alongside a syndicate of underwriters, including Beacon Securities Limited, Cormark Securities Inc., Echelon Wealth Partners Inc., and PI Financial Corp.

The Offered Securities were offered in each of the Provinces of Canada, other than the Province of Québec, pursuant to a prospectus supplement to the Company’s base shelf prospectus dated May 14, 2019 (the “Prospectus”), in the United States on a private placement basis pursuant to applicable exemptions from the registration requirements of the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) and elsewhere on a private placement basis.

Net proceeds from the Offering are expected to be used primarily to fund Trulieve’s business development and for general working capital purposes. The Company has made the required filings to list the Offered Securities on the Canadian Securities Exchange.‎

Copies of the Prospectus may be obtained on SEDAR at and from Canaccord Genuity Corp., 161 Bay Street, Suite 3000, Toronto, ON M5J 2S1. The Prospectus contains important detailed information about the Company and the Offering. Prospective investors should read the Prospectus and the other documents the Company has filed on SEDAR at before making an investment decision.

No securities regulatory authority has either approved or disapproved of the contents of this news release. The subordinate voting shares have not been and nor will they be registered under the U.S. Securities Act or any state securities laws. Accordingly, the subordinate voting shares may not be offered or sold within the United States unless registered under the U.S. Securities Act and applicable state securities laws or pursuant to exemptions from the registration requirements of the U.S. Securities Act and applicable state securities laws. This news release does not constitute an offer to sell or a solicitation of an offer to buy any securities of Trulieve in any jurisdiction in which such offer, solicitation or sale would be unlawful.

About Trulieve

Trulieve is a vertically integrated “seed-to-sale” company and is the first and largest fully licensed medical cannabis company in the State of Florida. Trulieve cultivates and produces all of its products in-house and distributes those products to Trulieve-branded stores (dispensaries) throughout the State of Florida, as well as directly to patients via home delivery. Trulieve also operates in California, Massachusetts and Connecticut. Trulieve is listed on the Canadian Securities Exchange under the symbol TRUL and trades on the OTCQX Best Market under the symbol TCNNF. Learn more at:

Forward-Looking Statements

This news release includes forward-looking information and statements, which may include, but ‎are not limited to, information and statements regarding or inferring the future business, ‎operations, financial performance, prospects, and other plans, intentions, expectations, estimates, ‎and beliefs of the Company and statements with regard to the Offering, the intended use of the net proceeds of the Offering, and the listing of the Offered Securities on the Canadian Securities Exchange. Words such as “expects”, ‎‎“continue”, “will”, “anticipates” and “intends” or similar expressions are intended to identify ‎forward-looking statements. These forward-looking statements are based on the Company’s ‎current projections and expectations about future events and financial trends that management ‎believes might affect its financial condition, results of operations, business strategy and financial ‎needs, and on certain assumptions and analysis made by the Company in light of the experience ‎and perception of historical trends, current conditions and expected future developments and ‎other factors management believes are appropriate. Forward-looking information and statements ‎involve and are subject to assumptions and known and unknown risks, uncertainties, and other ‎factors which may cause actual events, results, performance, or achievements of the Company ‎to be materially different from future events, results, performance, and achievements expressed ‎or implied by forward-looking information and statements herein. Such factors include, among others: risks and uncertainties relating to the actual use of the net proceeds of the Offering and the risks identified in the Company’s reports and filings with the applicable Canadian securities regulators, including, without limitation, all risks included in and incorporated by reference into the Prospectus. Although the Company ‎believes that any forward-looking information and statements herein are reasonable, in light of ‎the use of assumptions and the significant risks and uncertainties inherent in such information ‎and statements, there can be no assurance that any such forward-looking information and ‎statements will prove to be accurate, and accordingly readers are advised to rely on their own ‎evaluation of such risks and uncertainties and should not place undue reliance upon such ‎forward-looking information and statements. Any forward-looking information and statements ‎herein are made as of the date hereof, and except as required by applicable laws, the Company ‎assumes no obligation and disclaims any intention to update or revise any forward-looking ‎information and statements herein or to update the reasons that actual events or results could or ‎do differ from those projected in any forward looking information and statements herein, whether ‎as a result of new information, future events or results, or otherwise, except as required by ‎applicable laws.‎

The Canadian Securities Exchange has not reviewed, approved or disapproved the ‎content of this news release.‎

Lynn Ricci
Director, Investor Relations & Corporate Communications               

Ryan Ferguson


Abbott Receives CE Mark for Next-Generation MitraClip™ Heart Valve Repair Device to Treat Mitral Regurgitation

– CE Mark for MitraClip G4 offers physicians an innovative next-generation system with more options for mitral valve repair using proven clip-based technology

– MitraClip is a first-of-its-kind transcatheter mitral valve therapy, now on its fourth generation, improving further on MitraClip’s history as a safe and effective treatment option

PR Newswire

ABBOTT PARK, Ill., Sept. 21, 2020 /PRNewswire/ — Abbott (NYSE: ABT) today announced it has received CE Mark for its fourth-generation MitraClip™ Transcatheter Mitral Valve Repair System, the leading minimally invasive mitral valve repair device in the world. Known as MitraClip G4, the device is now approved for use in Europe and other countries that recognize CE Mark as a non-surgical option for the treatment of mitral regurgitation (MR), or a leaky heart valve. The device is already approved for use in the U.S.

The MitraClip G4 system provides physicians in Europe with enhancements to MitraClip’s first-of-its-kind clip-based technology, building upon the device’s proven delivery system. In addition to offering advanced steering during implantation, the new delivery system offers four clip sizes, including two wider clips, for doctors to have a greater variety of treatment options that can be tailored to a patients’ unique mitral valve anatomy.1 The newest-generation device also offers independently controlled grippers, if needed, that allow physicians to grasp one or both mitral valve leaflets at a time during the MitraClip procedure.

MR is one of the most common heart conditions, affecting one in 10 adults age 75 and older.2,3 Patients with this progressive condition have a mitral valve that does not close completely, allowing blood to flow backward into the left atrium of the heart instead of forwards (out of the heart) and to the rest of the body. While medication can help people manage the symptoms of MR, it does not treat the leaky valve itself. Prior to MitraClip, open-heart surgery was the standard treatment for MR, however, not all patients are eligible or appropriate for open-heart surgery due to the potential risk of complications stemming from comorbidities, advanced age or other issues.

MitraClip is a first-of-its-kind minimally invasive transcatheter mitral valve repair (TMVr) therapy that can be a life-saving treatment option for select patients with primary or secondary MR.4 The small clip-based device is delivered to the heart through a vein in the leg and clips portions of the leaflets, or flaps, of the mitral valve together to reduce the backflow of blood. Once in place, MitraClip restores the proper functioning of the mitral valve and the heart’s ability to pump oxygenated blood more efficiently.

“Despite being consistently recognized as a problem in patients around the world, MR cannot be treated through the conventional method of open-heart mitral valve surgery in more than half of the people who have this condition,” said Ralph Stephan Von Bardeleben, head of the Heart Valve Center Mainz, Universitätsmedizin Mainz, Germany, who treated the first MitraClip G4 patients in the EU. “The newest MitraClip therapy offers physicians a reliable option when surgical treatment of MR isn’t possible or appropriate, and MitraClip G4’s enhancements allow further customization of the therapy to tailor treatment to individual patient needs.” 

MitraClip is backed by more than 16 years of clinical experience with proven safety, survival and durable clinical outcomes. Data presented at PCR e-Course this year from a real-world clinical study of over 1,000 MitraClip patients showed a high implant success rate (99%) and demonstrated MR reduction to the level of none or trace in patients with either primary MR (to ≤1+ in 87.1%) or secondary MR (to ≤1+ in 90.1%) at 30 days. This recent data confirms MitraClip’s best-in-class MR reduction to date1 and adds to a body of evidence that demonstrates significant impact for patients, including improved clinical outcomes and quality of life.

“An enduring measure of our mission to help people live better lives through better health is our success in advancing new standards of care for the treatment of structural heart diseases,” said Michael Dale, senior vice president of Abbott’s structural heart business. “This CE Mark, along with other recent approvals and advancements for our MitraClip device, underscores the need for MitraClip’s innovative therapy – which has become a preferred choice for the treatment of mitral regurgitation around the world.”

The MitraClip system has been commercially available in the U.S. since 2013 and in Europe since 2008. Recent regulatory milestones for the device include the first-ever commercial introduction of MitraClip therapy to China and approval in Japan for the fourth generation of MitraClip, both in June of 2020. These milestones are of critical importance for the Asia-Pacific region where many people suffer from MR but may not have had a treatment option available to them. Since its initial approval, more than 100,000 people have been treated with MitraClip in all major regions around the world.

For U.S. important safety information on MitraClip™ visit  

About Abbott:

Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 107,000 colleagues serve people in more than 160 countries.

Connect with us at, on LinkedIn at, on Facebook at and on Twitter @AbbottNews and @AbbottGlobal.

1 Rottbauer W. D. Contemporary Clinical Outcomes with MitraClip™ (NTR/XTR) System: Core-lab Echo Results from +1000 Patient the Global EXPAND Study. Data presented at PCR 2020.
2 Lloyd-Jones D, Adams RJ, Brown TM, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2010 update: a report from the American Heart Association. Circulation. 2010;121(7):e46-e215.
3 Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enriquez-Sarano M. Burden of valvular heart diseases: a population-based study. Lancet. 2006;368(9540):1005-1011.
Primary MR is caused by an anatomic defect of one or more of the structures of the mitral valve of the heart, while secondary MR occurs in patients with coronary disease, wherein the damage from the disease impairs the performance of a normal mitral valve. 


Cision View original content:


iQIYI Announces Partnership with WWE® , Delivering Entertainment Experience to Chinese Audiences

PR Newswire

BEIJING, Sept. 21, 2020 /PRNewswire/ — iQIYI Sports (the “Platform”), a joint venture between iQIYI, Inc. (NASDAQ:IQ) (“iQIYI” or the “Company”), an innovative market-leading online entertainment service in China, and Super Sports Media, today announced it has reached a partnership with WWE® (NYSE: WWE) in which WWE’s weekly flagship programming will be released live and in mandarin to audiences in China’s Mainland starting September 22. Under the partnership, iQIYI Sports will offer on its platform content from the popular WWE brands Raw® and SmackDown®, as well as a WWE subscription video-on-demand service featuring all of WWE’s monthly pay-per-view events, including classic matches such as Royal Rumble, WrestleMania, SummerSlam and the Survivor Serie.

WWE content on iQIYI Sports will be made available to viewers in HD while dual Chinese and English commentaries will also be available for viewers to choose from. iQIYI Sports’ WWE content will be accessible to users who have the regular iQIYI Sports membership or the iQIYI Sports boxing membership.

WWE is an integrated media organization and recognized leader in global entertainment. The company boasts an extensive business portfolio that creates and delivers original content all year round to a global audience. WWE is committed to family friendly entertainment on its television programming, pay-per-view, digital media and publishing platforms. WWE programming is available in more than 800 million households worldwide and broadcasts to more than 180 countries and in 28 languages. The company has helped launch the careers of pop-culture icons including Dwayne “The Rock®” Johnson, John Cena®, Triple H®, “Stone Cold®Steve Austin® and The Bella Twins.

“We are thrilled to begin an exciting new chapter for WWE in the region as we bring our unique blend of action-packed, family-friendly sports entertainment to iQIYI Sport’s impressive portfolio of premium sports content,” said Jay Li, WWE Vice President & General Manager, Greater China.

“I have full confidence in this partnership,” said Lingxiao Yu, CEO of iQIYI Sports. “WWE is loved by many fans around the world and has a huge fan base in China. We are pleased to become partners with WWE. We will leverage the resources of our platform to ensure that top quality WWE content is delivered to Chinese audiences as an unbeatable entertainment experience.”

Going forward, iQIYI Sports will incorporate innovative technologies into the livestreams of WWE content. In addition to introducing user interaction features such as Bullet Subtitles, widely known as Danmu, during WWE livestreams, iQIYI Sports will also be collaborating with WWE to develop interactive content.

For more information, please visit iQIYI Sports’ WWE Channel at:

About iQIYI, Inc.

iQIYI, Inc. is an innovative market-leading online entertainment service in China. Its corporate DNA combines creative talent with technology, fostering an environment for continuous innovation and the production of blockbuster content. iQIYI’s platform features highly popular original content, as well as a comprehensive library of other professionally-produced content, partner-generated content and user-generated content. The Company distinguishes itself in the online entertainment industry by its leading technology platform powered by advanced AI, big data analytics and other core proprietary technologies. iQIYI attracts a massive user base with tremendous user engagement, and has developed a diversified monetization model including membership services, online advertising services, content distribution, live broadcasting, online games, IP licensing, online literature and e-commerce.

About iQIYI Sports

As a leading sports video streaming platform in China, iQIYI Sports has always been committed to building a multi-dimensional content ecosystem to provide users with high-quality sports content. At present, iQIYI Sports holds a large number of top-tier sports properties including LaLiga, UEFA EURO 2020, FIFA World Cup qualification-AFC, major tennis and golf tournaments, world-class fighting games and many other popular sporting events. In addition, iQIYI Sports is also dedicated to producing original high-quality sports programs to meet the personalized needs of pan-sports users and vertical sports users from different perspectives. In the future, iQIYI Sports will continue to innovate product technical forms and user interaction methods to provide a more customized experience to every sports fan on the platform.

About WWE

WWE, a publicly traded company (NYSE: WWE), is an integrated media organization and recognized leader in global entertainment. The company consists of a portfolio of businesses that create and deliver original content 52 weeks a year to a global audience. WWE is committed to family friendly entertainment on its television programming, pay-per-view, digital media and publishing platforms. WWE programming reaches more than 800 million homes worldwide in 28 languages. WWE Network, the first-ever 24/7 over-the-top premium network that includes all live pay-per-views, scheduled programming and a massive video-on-demand library, is currently available in more than 180 countries. The company is headquartered in Stamford, Conn., with offices in New York, Los Angeles, London, Mexico City, Mumbai, Shanghai, Singapore, Dubai, Munich and Tokyo. Additional information on WWE (NYSE: WWE) can be found at and For information on our global activities, go to

Cision View original content:–delivering-entertainment-experience-to-chinese-audiences-301134659.html


System Surveyor Advances Remote Collaboration and Co-Design Features for Security Industry

Upgraded SaaS Customer Engagement Platform Includes Enhanced Digital Communication, New Accessories Support, and Professional Reporting

Austin, Sept. 21, 2020 (GLOBE NEWSWIRE) — System Surveyor has released three major enhancements to its mobile, graphical system design and customer engagement platform used by thousands of security professionals. New survey comments, accessories, and enhanced reporting features will help project teams better streamline the system design process as well as collaborate across geographic and organizational boundaries.

The new release includes:

Survey Comments: Using the new “Survey Comments” feature, security pros can easily communicate with other users from within the System Surveyor application. For example, during project implementation, a project manager can easily add a comment notifying the installation team of a new customer requirement. A commonly recognized @user mention alerts specific project team members to any new comments. They can comment back or take action, cutting down on difficult-to-find emails and texts or other external communications. This can be especially helpful with teams that work remotely from each other.

Device Accessories: One of the most requested feature enhancements is the ability to plan for accessories such as mounting brackets for video surveillance cameras or faceplates for door hardware. Now users can add this additional piece of equipment and automatically associate it with the related component. Device Accessories will be included in System Surveyor’s Budget Estimator feature as well as Enhanced Reports and Bill of Materials related to the device.

Enhanced Reports: Enhanced Reports exploit System Surveyor’s drag-and-drop design to automate the Bill of Materials for a project in one step. This makes reporting more powerful, flexible, and easier to use. While the Classic Reports options will still be available, the new Enhanced Reports are cleaner and more professional, with a branded format that is client or stakeholder ready.

“Our customers are continually suggesting new, innovative features and functionality to help them serve their customers and stakeholders better. This new release expands the ability to co-design with their clients and facilitate a more complete customer experience,” said Chris Hugman, CEO of System Surveyor. “Our new in-app communication capabilities and improved bill of materials report will help streamline the supply chain and accelerate project schedules. Our world-class software development team has really delivered, balancing these advanced features with ease of use.”

How to learn more:

About System Surveyor:

System Surveyor mobile, SaaS-based platform enables everyone involved in system design, installation, and maintenance to collaborate on an unprecedented scale. Working together in one system of record, professionals can better plan and manage the systems organizations rely on every day: video surveillance, CCTV, access control, fire alarm, IT, building automation, AV, healthcare, and more. From system integrators to end customers to subcontractors, the benefits are increased sales, faster project completions, higher satisfaction, and enhanced long-term service levels. Try all features and collaboration of the product for free with a 5 person team for up to 21 days. Based in Austin, Texas, System Surveyor can be found at


Chandra Hosek
H2 Strategic Communications

Pentair Announces 2019 Corporate Responsibility Report: Smart, Sustainable Solutions. For Life.

Pentair Announces 2019 Corporate Responsibility Report: Smart, Sustainable Solutions. For Life.

Global water treatment company Pentair (NYSE: PNR) announces the release of its 2019 Corporate Responsibility (CR) Report, highlighting its corporate and community citizenship efforts to make a positive impact for its customers, employees, communities and the global environment that Pentair strives to improve through smart, sustainable solutions.

This press release features multimedia. View the full release here:

Global water treatment company Pentair announces the release of its 2019 Corporate Responsibility (CR) Report. (Graphic: Business Wire)

Global water treatment company Pentair announces the release of its 2019 Corporate Responsibility (CR) Report. (Graphic: Business Wire)

“Our mission, to deliver smart, sustainable solutions, drives all that we do and empowers our employees to make a difference within and beyond the workplace,” said John L. Stauch, Pentair President and CEO. “Through our purpose, products and people, we are focused on helping to make the world a more sustainable place. This is core to Pentair and central to our vision in building a leading water treatment company.”

Featured within the report are success stories demonstrating Pentair’s efforts to support a more sustainable future. Highlights include:

  • Launched an array of water and energy efficient solutions for residential and commercial applications, including a streamlined product portfolio of energy efficient pumps for commercial building applications that exceed the U.S. Department of Energy (DOE) pump efficiency standards that went into effect in January 2020.
  • Partnered with Major League Baseball team the Minnesota Twins to install filtration technology at nine Pentair Water Filtration Stations throughout Target Field, helping to reduce plastic bottle waste at the ballpark.
  • Introduced a new Employee Emergency Fund to provide tax-free emergency hardship grants to employees dealing with unexpected and unavoidable financial hardships.

Additionally, the report highlights initiatives the company is taking to reduce the environmental impact of its own operations. From 2016 to 2019, Pentair reduced its own municipal water withdrawals at its plants by more than seven million gallons. The company also reported year-over-year decreases in energy consumption and carbon dioxide (CO2) emissions from 2018 to 2019, and recycled or reused more than 77 percent of waste from manufacturing.

To view and download Pentair’s 2019 Corporate Responsibility Report, click here.


At Pentair, we believe the health of our world depends on reliable access to clean, safe water. We deliver a comprehensive range of smart, sustainable water solutions to homes, business and industry around the world. Our industry leading and proven portfolio of solutions enables our customers to access clean, safe water. Whether it’s improving, moving or enjoying water, we help manage the world’s most precious resource. Smart, Sustainable Water Solutions. For Life.

Pentair had revenue in 2019 of $3 billion, and trades under the ticker symbol PNR. With approximately 120 locations in 25 countries and 9,500 employees, we believe that the future of water depends on us. To learn more, visit

Rebecca Osborn – Pentair Communications

Direct: +1 763 656 5589


KEYWORDS: United Kingdom Europe

INDUSTRY KEYWORDS: Other Natural Resources Utilities Manufacturing Energy Natural Resources Other Manufacturing


Global water treatment company Pentair announces the release of its 2019 Corporate Responsibility (CR) Report. (Graphic: Business Wire)

Travelers Introduces AI-Based Ergonomic Assessments

Travelers Introduces AI-Based Ergonomic Assessments

New capability can be used on-site and virtually to deliver expedited safety recommendations

The Travelers Companies, Inc. (NYSE: TRV) today announced that it is the first insurance carrier to offer its business customers virtual and on-site ergonomic assessments using artificial intelligence (AI).

The new offering combines AI-based technology and ergonomic research to quickly analyze a smartphone video of a worker performing a task and identify movements and postures that could cause injuries. The software then quantifies the risk and produces a report that assists a Travelers ergonomics professional in developing consultative solutions that help keep workers safe.

“Musculoskeletal injuries, often caused by poor ergonomics or workstation design, can lead to serious health issues that can impair an employee’s ability to perform certain tasks or require them to take time off to recover,” said Marty Henry, Senior Vice President of Risk Control at Travelers. “By using AI, we can reduce the time spent assessing problems from days to hours, enabling our specialists to focus their attention on developing tailored workplace improvements for our customers.”

Ergonomic assessments can be used to assist businesses of all sizes in establishing processes that enhance workplace safety. Making appropriate adjustments can help reduce the frequency of common injuries and better control workers compensation costs.

“We understand our customers’ concerns with offering visitors access to their locations during this challenging period,” said Mary Ellen Ausenbaugh, Technical Director of Human Factors and Ergonomics at Travelers. “Enhancing our existing virtual option to enable remote ergonomic assessments using smartphone video is another innovative way that we are helping our customers maintain high levels of safety as we all operate differently.”

For more information about Travelers Risk Control and Ergonomics Consulting Services, please visit

About Travelers

The Travelers Companies, Inc. (NYSE: TRV) is a leading provider of property casualty insurance for auto, home and business. A component of the Dow Jones Industrial Average, Travelers has approximately 30,000 employees and generated revenues of approximately $32 billion in 2019. For more information, visit


Kate Thermansen, 860.954.1789

KEYWORDS: Connecticut United States North America

INDUSTRY KEYWORDS: Software Mobile/Wireless Internet Professional Services Technology Commercial Building & Real Estate Construction & Property Trucking Insurance Audio/Video Human Resources Transport



China Ceramics Regains Compliance with NASDAQ Listing Requirements

PR Newswire

JINJIANG, China, Sept. 21, 2020 /PRNewswire/ — China Ceramics Co., Ltd. (NASDAQ Capital Market: CCCL) (“China Ceramics” or the “Company”), a leading Chinese manufacturer of ceramic tiles used for exterior siding and for interior flooring and design in residential and commercial buildings, today announced that it has received a letter from the Listings Qualifications Department of The Nasdaq Stock Market notifying the Company that it has regained compliance with NASDAQ’s minimum bid requirements for continued listing requirements on the NASDAQ Stock Market. On September 3, 2020, the Company effected a one-for-three reverse stock split to regain compliance with the minimum bid price requirement of $1.00 per share for continued listing on the NASDAQ Stock Market. The letter noted that since the closing bid of the Company’s common stock has been $1.00 per share or more for 10 consecutive business days, from September 3, 2020 to September 18, 2020, the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2) and that the matter is now closed.

About China Ceramics Co., Ltd.

China Ceramics Co., Ltd. is a leading manufacturer of ceramic tiles in China. The Company’s ceramic tiles are used for exterior siding, interior flooring, and design in residential and commercial buildings. China Ceramics’ products, sold under the “Hengda” or “HD”, “Hengdeli” or “HDL”, the “TOERTO” and “WULIQIAO” brands, and the “Pottery Capital of Tang Dynasty” brands, are available in over 2,000 style, color and size combinations and are distributed through a network of exclusive distributors as well as directly to large property developers. Through its wholly-owned subsidiary, Antelope Holdings (Chengdu), Co., Ltd., the Company provides fintech solutions which includes the development of blockchain software. For more information, please visit

Cautionary Note Regarding Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties, including statements relating to the Company’s ability to, among other things, successfully design, deploy and pursue this expansion strategy, the Company’s ability to complete any agreements with new customers in the markets in question and add to its overall growth. Actual events or results may differ materially from the Company’s expectations. Factors that could cause actual results to differ materially from those stated or implied by the Company’s forward-looking statements are disclosed in its filings with the Securities and Exchange Commission. These forward-looking statements represent the Company’s judgment as of the time of this release. The Company disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

Cision View original content:

SOURCE China Ceramics Co., Ltd.

Arthur J. Gallagher & Co. Acquires The Merriam Agency

PR Newswire

ROLLING MEADOWS, Ill., Sept. 21, 2020 /PRNewswire/ — Arthur J. Gallagher & Co. (NYSE: AJG) today announced the acquisition of Charles W. Merriam & Son, Inc., dba The Merriam Agency. Terms of the transaction were not disclosed.

Founded in 1895, The Merriam Agency is a full-service insurance agency with offices in upstate N.Y. (including Schenectady) and Colorado Springs, Colo. The team offers a full range of commercial, personal lines and employee benefits coverages and services, and specializes in serving nonprofit and social service clients across the United States. Brian Merriam and his team will operate under the direction of Patrick Kennedy, head of Gallagher’s Northeast region retail property/casualty brokerage operations.

“The Merriam Agency has been serving the nonprofit community for 125 years! Their deep expertise and long-standing relationships in that market will complement and expand Gallagher’s existing strengths,” said J. Patrick Gallagher, Jr., Chairman, President and CEO. “We are very pleased to welcome Brian and his associates to our growing, global team.”

Arthur J. Gallagher & Co., a global insurance brokerage, risk management and consulting services firm, is headquartered in Rolling Meadows, Illinois. The company has operations in 49 countries and offers client-service capabilities in more than 150 countries around the world through a network of correspondent brokers and consultants.

Investors:  Ray Iardella

Media:  Linda J. Collins

VP – Investor Relations

VP – Corporate Communications




Cision View original content to download multimedia:–co-acquires-the-merriam-agency-301134284.html

SOURCE Arthur J. Gallagher & Co.

Eurofins Discovery In Vitro Pharmacology SafetyScreen44™ Panels Further Increase the Value of Molecules

PR Newswire

ST. CHARLES, Mo., Sept. 21, 2020 /PRNewswire/ — Eurofins Discovery, the leading provider of services and products to the drug discovery industry, today announced a new project with Boehringer Ingelheim’s open innovation portal, As part of this project, Eurofins Discovery has worked together with Boehringer Ingelheim to profile the entire opnMe portfolio of small molecules for the assessment of their selectivity by using its gold standard SafetyScreen44 in vitro pharmacology panel, which enables early identification of significant off-target interactions related to in vivo adverse effects, with the goal to further increase value to scientists which work with the opnMe molecules.

Boehringer Ingelheim is sharing well-characterized preclinical tool compound molecules with scientists around the world to enable more scientific opportunities and achieve the ultimate aim of bringing more medical breakthroughs to patients in need. The chemical structure and the data package for these compounds are disclosed on the portal without any conditions. All molecules are provided free of charge on These molecules are derived from Boehringer Ingelheim’s discovery research pipeline, or were developed in collaboration with external partners of Boehringer Ingelheim. With this “molecules to order” open innovation program, Boehringer Ingelheim aims to help scientists validate their scientific hypotheses and independently publish their data to advance science more quickly.

Boehringer Ingelheim puts high emphasis on the quality of its opnMe molecules. Many are provided with a negative control that can be used to validate research experiments. In addition, a good understanding of their selectivity profile is mandatory for the interpretation of any scientific results. For this reason, Boehringer Ingelheim is now applying Eurofins Discovery’s in vitro pharmacology SafetyScreen44 panel to its entire opnMe portfolio and has made available the results for the current molecules via

This further increases the value of this unique set of molecules which are provided free with the scientific community.

With the enhanced data achieved from the project, researchers can obtain high quality molecules for their own experiments, which are now supplemented with reliable and valuable profiling data.

Learn more about Eurofins Discovery’s In Vitro Pharmacology services at

Access Boehringer Ingelheim’s open innovation portal and their molecule profiles at:

About Eurofins – the global leader in bio-analysis

Eurofins Scientific, through its subsidiaries (hereinafter “Eurofins” or “the Group”), believes it is the global leader in food, environmental, pharmaceutical and cosmetics products testing and in agroscience CRO services. It is also one of the global independent market leaders in certain testing and laboratory services for genomics, discovery pharmacology, forensics, CDMO, advanced material sciences and in the support of clinical studies. In addition, Eurofins is one of the leading global emerging players in esoteric and molecular clinical diagnostic testing. With over 48,000 staff across a network of more than 900 independent companies in over 50 countries generally specialised by end client markets and operating more than 800 laboratories, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of a wide range of products, as well as providing innovative clinical diagnostic testing services. The Group’s objective is to provide customers with high-quality and innovative services, accurate results on time and, when requested, expert advice by its highly-qualified staff.

Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions and a very large range of testing methods.

As one of the most innovative and quality-oriented international groups in its industry, Eurofins is ideally positioned to support its clients’ increasingly stringent quality and safety standards and the increasing demands of regulatory authorities and healthcare practitioners around the world.

Shares in Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP).

About opnMe, the new open innovation portal of Boehringer Ingelheim, aims to accelerate research initiatives to enable new insights of disease biology in areas of high unmet medical need by sharing well-characterized molecules and offer collaborations for science. In the spirit of collaboration, the molecules are provided to the scientific community to help unlock and fulfill their full potential. These molecules are either freely available as “Molecules to Order” or applied via scientific research submissions as “Molecules for Collaboration”. As part of a third pillar, the “opn2EXPERTS” program, Boehringer Ingelheim also enlist scientific advice on key biologic issues to fuel further drug discovery and deliver novel solutions that benefit unmet patient needs.

Cision View original content to download multimedia:

SOURCE Eurofins Discovery

Carlyle Makes Strategic Growth Investment in TriNetX; Acquires Majority Stake in Leading Global Health Research Network

Investment Will Accelerate Development of New Clinical Research Capabilities for Healthcare Organizations and Life Sciences Customers, With the Aim of Capitalizing on Both Organic and Inorganic Growth Opportunities

PR Newswire

NEW YORK and CAMBRIDGE, Mass., Sept. 21, 2020 /PRNewswire/ — TriNetX (, the leading global health research network optimizing clinical research to bring new therapies to market faster, today announced global investment firm The Carlyle Group (NASDAQ: CG) has made a strategic growth investment and will acquire a majority stake in the Company. Terms of the transaction were not disclosed. 

Since its founding in 2013, TriNetX has built the largest global network of research hospitals and academic institutions, top biotech and pharmaceutical companies, contract research organizations (CROs) and other specialty data partners. TriNetX is powered by an impressive network of 170 healthcare organizations in 30 countries and used by more than 40 life sciences organizations including 15 of the world’s top 20 pharmaceutical companies.

“Our goal is to be on the desktop of every healthcare researcher in the world,” said Gadi Lachman, CEO of TriNetX. “To accomplish this we need to continue to develop solutions to support clinical research at our healthcare organizations and bring more global data and technologies such as AI, machine learning and analytics to researchers so that they can ask more questions and generate more real-world evidence. Carlyle’s investment accelerates our growth plans and will shorten the time it takes to turn our vision into reality.”

TriNetX enables researchers to apply a data-driven approach to health research by providing web-based, on-demand access to harmonized global electronic health record (EHR) and claims data with a suite of highly intuitive analytics. TriNetX is utilized in all parts of the drug development cycle, including protocol design and feasibility, site selection and patient identification for clinical trials, as well as serving clinical research for drugs already in the market to help researchers understand efficacy, risks and other market dynamics and to generate real-world evidence (RWE) to support hypothesis and decision making, in real-time.

The longitudinal clinical and claims data representing over 400 million patients available through TriNetX is mapped to controlled terminology and consists of clinical facts from hundreds of healthcare organizations around the world, deep specialty data for all therapeutic areas, including COVID-19, cardiovascular, oncology, and rare disease, and linked medical claims, pharmacy claims and EHR data.

“With a deep clinical focus and a highly scalable data strategy, we believe TriNetX is well positioned for continued organic and inorganic growth opportunities,” said Joe Bress, a Principal specializing in healthcare at The Carlyle Group. “We’re excited to partner with Gadi and the TriNetX management team to help expand their global footprint and continue investing in the company’s mission to advance the collective understanding of human health.”

The investment in TriNetX is a continuation of Carlyle’s long-term global commitment to healthcare, in which it has invested more than $15 billion of equity since inception. Equity capital for the investment came from Carlyle Partners VII, an $18.5 billion fund that makes majority and strategic minority investments primarily in the U.S. in targeted industries, including healthcare.

SVB Leerink served as exclusive financial advisor to TriNetX.

About The Carlyle Group

The Carlyle Group (NASDAQ: CG) is a global investment firm with deep industry expertise that deploys private capital across four business segments: Corporate Private Equity, Real Assets, Global Credit and Investment Solutions. With $221 billion of assets under management as of June 30, 2020, Carlyle’s purpose is to invest wisely and create value on behalf of its investors, portfolio companies and the communities in which we live and invest. The Carlyle Group employs more than 1,800 people in 31 offices across six continents. Further information is available at Follow The Carlyle Group on Twitter @OneCarlyle

About TriNetX
TriNetX is the global health research network that connects the world of drug discovery and development from pharmaceutical company to study site, and investigator to patient by sharing real-world data to make clinical and observational research easier and more efficient. TriNetX combines real time access to longitudinal clinical data with state-of-the-art analytics to optimize protocol design and feasibility, site selection, patient recruitment, and enable discoveries through the generation of real-world evidence. The TriNetX platform is HIPAA and GDPR compliant. For more information, visit TriNetX at or follow @TriNetX on Twitter.

Media Contacts:

Brittany Berliner

+1 (212) 813 4839

Jennifer Haas

+ 1 (978) 697 3921

Cision View original content to download multimedia: